Last reviewed · How we verify

Preservative-free epidural morphine

Mount Sinai Hospital, Canada · FDA-approved active Small molecule

Morphine binds to opioid receptors in the spinal cord and brain to block pain signal transmission and provide analgesia.

Morphine binds to opioid receptors in the spinal cord and brain to block pain signal transmission and provide analgesia. Used for Acute postoperative pain, Chronic cancer pain, Chronic non-cancer pain.

At a glance

Generic namePreservative-free epidural morphine
Also known asMorphine, Epidural Narcotics
SponsorMount Sinai Hospital, Canada
Drug classOpioid analgesic
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Morphine is a mu-opioid receptor agonist that acts on opioid receptors in the central nervous system. When administered epidurally, it reaches opioid receptors in the spinal cord at lower systemic doses than oral or intravenous administration, providing potent analgesia with reduced systemic side effects. The preservative-free formulation minimizes neurotoxicity and irritation to neural tissue.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: